Cyclosporin a as an Add-On Therapy to a High Dose Corticosteroid-Based Background Treatment in Patients With COVID-19: A Multicenter Randomized Clinical Trial
Clinical endpoint
Intention-to-treat analysis
DOI:
10.20944/preprints202407.2075.v1
Publication Date:
2024-07-30T11:00:41Z
AUTHORS (12)
ABSTRACT
Background: In susceptible hosts, SARS-CoV2 induced hyperinflammation accounts for an increased mortality. The search of adjuvant immunomodulatory therapies has been ongoing ever since the pandemic outbreak. Aim: Our purpose was to evaluate efficacy cyclosporin A (CsA) as add-on therapy standard care in patients with severe COVID-19 pneumonia. Methods: We conducted a randomized clinical trial admitted 8 Spanish Tertiary Hospitals. Patients were stratified into two severity categories and 1:1 receive high dose corticosteroid-based or without CsA. primary endpoint FiO2 recovery by day 12 relapses. Results: 109 included 98 randomized: 51 them assigned CsA+SoC group 47 Standard Care (SoC). 96/98 Intention Treat population. 35 (68.6%) from 32 (71,1%) SoC reached ITT analysis. No differences found after stratification age groups, level at admission combination both. Overall, time normalization 7.4 days vs 7.9 experimental control respectively. Global mortality 8.2%. Severe adverse events uncommon equally distributed between arms. Conclusion: Addition CsA did not show over high-dose corticosteroids-based treatment course patients. better identification candidates who will benefit receiving drugs is necessary future studies.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....